Abstract
Anemia in cancer patients is associated with reduced quality of life and local failure after radiation treatment. However, the use of erythropoietin to correct cancer anemia and to improve radiation efficacy was disappointing. Erythropoietin-receptor signaling mainly acts via activation of STAT 5, but also crossactivates the antiapoptotic transcription factor NF-κB. This causes neuroprotection against oxidative stress and implies radioprotection. In order to investigate possible radioprotective effects of erythropoietin-receptor signaling, we used an in vitro model system employing HeLa TetOff cells, stably transfected with an expression vector for the erythropoietin-receptor gene. Using electrophoretic mobility shift assays, we could demonstrate strong activation of NF-κB by erythropoietin-receptor signaling in HeLa cells. Activation of NF-κB did not require degradation of IκBα and was not prevented by proteasome inhibition. Furthermore, stimulation with erythropoietin resulted in a 50% increased clonogenicity of erythropoietin-receptor-expressing cells but did not alter radiation sensitivity itself. As most human tumors express erythropoietin receptor, we advocate a restricted use erythropoietin to patients suffering from erythropoietin-receptor-expressing cancers.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K and Verma A . (2001). Cancer Res., 61, 3561–3565.
Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, Liu S, Lu H and Verma A . (2003). Am. J. Pathol., 162, 1789–1806.
Albright N . (1987). Radiat. Res., 112, 331–340.
Baeuerle PA and Baltimore D . (1996). Cell, 87, 13–20.
Batr AS, Perelman N, Luck LR, Shimada H and Malik P . (2003). Lab. Invest., 83, 1477–1487.
Buemi M, Cavallaro E, Floccari F, Sturiale A, Aloisi C, Trimarchi M, Corica F and Frisina N . (2003). J. Neuropathol. Exp. Neurol., 62, 228–236.
Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A and Brines M . (2003). Proc. Natl. Acad. Sci. USA, 100, 4802–4806.
Damen JE and Krystal G . (1996). Exp. Hematol., 24, 1455–1459.
Digicaylioglu M and Lipton SA . (2001). Nature, 412, 641–647.
Dunst J, Kuhnt T, Strauss HG, Krause U, Pelz T, Koelbl H and Haensgen G . (2003). Int. J. Radiat. Oncol. Biol. Phys., 56, 778–787.
Fallowfield L, Gagnon D, Zagari M, Cella D, Bresnahan B, Littlewood TJ, McNulty P, Gorzegno G and Freund M . (2002). Br. J. Cancer, 87, 1341–1353.
Frommhold H, Guttenberger R and Henke M . (1998). Strahlenther. Onkol., 174 (Suppl 4), 31–34.
Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E and Einhorn LH . (2001). J. Clin. Oncol., 19, 2875–2882.
Harrison LB, Shasha D and Homel P . (2002). Oncology, 63 (Suppl 2), 11–18.
Henke M, Laszig R, Rübe C, Schäfer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C and Frommhold H . (2003). Lancet, 262, 1255–1260.
Hirst DG, Hazlehurst JL and Brown JM . (1984). Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med., 46, 345–354.
Hirst DG and Wood PJ . (1987). Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med., 51, 597–609.
Imbert V, Rupec RA, Livolsi A, Pahl HL, Traenckner EB, Mueller-Dieckmann C, Farahifar D, Rossi B, Auberger P, Baeuerle PA and Peyron JF . (1996). Cell, 86, 787–798.
Joiner B, Hirst VK, McKeown SR, McAleer JJ and Hirst DG . (1993). Br. J. Cancer, 68, 720–726.
Jung M, Zhang Y, Lee S and Dritschilo A . (1995). Science, 268, 1619–1621.
Leyland-Jones B . (2003). Lancet Oncol., 4, 459–460.
Littlewood TJ, Bajetta E, Nortier JW, Vercammen E and Rapoport B . (2001). J. Clin. Oncol., 19, 2865–2874.
Pajonk F, Pajonk K and McBride WH . (1999). J. Natl. Cancer Inst., 91, 1956–1960.
Poskitt TR . (1987). Cancer Invest., 5, 231–236.
Ribatti D, Marzullo A, Nico B, Crivellato E, Ria R and Vacca A . (2003). Histopathology, 42, 246–250.
Santucci MA, Pierce JH, Zannini S, Fortuna A, Frezza G, Babini L, Rosenstein MM and Greenberger JS . (1994). Stem Cells, 12, 506–513.
Suwinski R, Taylor JM and Withers HR . (1999). Radiother. Oncol., 50, 57–66.
Verdier F, Chretien S, Muller O, Varlet P, Yoshimura A, Gisselbrecht S, Lacombe C and Mayeux P . (1998). J. Biol. Chem., 273, 28185–28190.
Westphal G, Niederberger E, Blum C, Wollman Y, Knoch TA, Rebel W, Debus J and Friedrich E . (2002). Tumori, 88, 150–159.
Acknowledgements
This work was funded by the Clotten Foundation, Freiburg, Germany.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pajonk, F., Weil, A., Sommer, A. et al. The erythropoietin-receptor pathway modulates survival of cancer cells. Oncogene 23, 8987–8991 (2004). https://doi.org/10.1038/sj.onc.1208140
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208140
Keywords
This article is cited by
-
Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020
Drugs (2021)
-
Impact of erythropoietin on the effects of irradiation under hypoxia
Journal of Cancer Research and Clinical Oncology (2009)
-
Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells
British Journal of Cancer (2008)
-
Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care
Medical Oncology (2008)
-
VEGF signaling inhibitors: More pro-apoptotic than anti-angiogenic
Cancer and Metastasis Reviews (2007)